NovaBay Pharmaceuticals I... (NBY)
AMEX: NBY
· Real-Time Price · USD
0.60
0.02 (3.45%)
At close: May 16, 2025, 3:59 PM
0.59
-1.19%
After-hours: May 16, 2025, 05:05 PM EDT
NovaBay Pharmaceuticals Revenue Breakdown
| Period Ending | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|
| Total Product Revenue Revenue | 9.75M | 14.69M | 14.37M | 8.4M | 9.92M |
| Total Product Revenue Revenue Growth | -33.64% | +2.18% | +71.18% | -15.32% | n/a |
Operating Expense Breakdown
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 2.7M | 2.78M | 2.65M | 2.64M | 3.35M | 2.61M | 2.94M | 3.63M | 3.64M | 4.38M | 2.79M | 3.66M | 3.87M | 4.61M | 3.63M | 3.36M | 2.87M | 2.8M | 3.57M | 2.9M | 2.84M | 3.33M | 2.88M | 2.73M | 5.14M | 4.69M | 4.57M | 4.34M | 5.02M | 4.8M | 5.61M | 5.11M | 6.83M | 5.25M | 4.88M | 4.11M | 4.8M | 5.95M | 4.36M | 4.37M | 3.41M |
| Selling, General, and Administrative Revenue Growth | -2.88% | +4.94% | +0.53% | -21.22% | +28.25% | -11.35% | -19.01% | -0.27% | -16.77% | +56.86% | -23.78% | -5.37% | -16.11% | +27.22% | +8.01% | +17.09% | +2.50% | -21.67% | +23.14% | +2.22% | -14.83% | +15.78% | +5.27% | -46.79% | +9.56% | +2.49% | +5.46% | -13.57% | +4.52% | -14.37% | +9.70% | -25.15% | +29.98% | +7.62% | +18.73% | -14.34% | -19.36% | +36.52% | -0.23% | +28.12% | n/a |
| Research and Development Revenue | n/a | 10K | 4K | 9K | 19K | 4K | 11K | 27K | 26K | 66K | 41K | 40K | 28K | 8K | 10K | 21K | 5K | 36K | 125K | 115K | 9K | 18K | 49K | 32K | 85K | 107K | 45K | 61K | 46K | 146K | 132K | 70K | 62K | 156K | 4K | 278K | 933K | 1.24M | 1.92M | 1.25M | 1.64M |
| Research and Development Revenue Growth | -100.00% | +150.00% | -55.56% | -52.63% | +375.00% | -63.64% | -59.26% | +3.85% | -60.61% | +60.98% | +2.50% | +42.86% | +250.00% | -20.00% | -52.38% | +320.00% | -86.11% | -71.20% | +8.70% | +1177.78% | -50.00% | -63.27% | +53.12% | -62.35% | -20.56% | +137.78% | -26.23% | +32.61% | -68.49% | +10.61% | +88.57% | +12.90% | -60.26% | +3800.00% | -98.56% | -70.20% | -24.70% | -35.47% | +54.22% | -24.13% | n/a |